After Stoke Therapeutics closed $90 million in financing last fall, CEO Ed Kaye signaled his biotech would seek more cash through an IPO soon. The preclinical-stage biotech is now officially on a path to the public markets.
In paperwork filed late Thursday with the SEC, Bedford, MA-based Stoke set a preliminary $86 million target for its IPO, which will fund its research on drugs to treat rare genetic diseases. The company has applied for a Nasdaq listing under the stock symbol “STOK.”
Stoke is developing treatments for diseases in which a genetic mutation leads to a protein deficiency. The company… Read more »
UNDERWRITERS AND PARTNERS